海王生物(000078) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was CNY 72,212,174.62, down 55.36% year-on-year[8]. - Operating revenue for the reporting period was CNY 10,879,441,068.10, an increase of 10.43% compared to the same period last year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 120,706,534.30, a decrease of 26.37% year-on-year[8]. - Basic earnings per share were CNY 0.0261, down 55.61% compared to the same period last year[8]. - The weighted average return on net assets was 1.12%, a decrease of 1.44% compared to the previous year[8]. - The company reported a net cash flow from operating activities of CNY 173,819,313.43, down 61.48% year-on-year[8]. - Net profit decreased by 35.22% compared to the same period last year, primarily impacted by the pandemic and the "4+7" volume-based procurement policy, leading to a decline in product gross margin[18]. - Operating net cash flow decreased by 61.48% compared to the same period last year, mainly due to lower gross margins and increased procurement costs[18]. - The company reported a significant increase in interest income to ¥120,252,029.10 from ¥198,465,019.08, indicating better cash management[61]. - The total profit before tax was ¥220,101,985.21, down from ¥335,909,249.83, highlighting a challenging operating environment[56]. - Net profit for the current period was ¥140,211,482.97, a decrease of 50% from ¥280,460,972.24 in the previous period[56]. - The net profit attributable to the parent company is ¥200,337,612.75, down from ¥365,546,214.53, indicating a decrease of 45.1%[74]. - The company incurred a tax expense of ¥200,384,388.47, compared to ¥250,942,806.07 in the previous period[72]. - The company’s operating profit for the current period is ¥667,046,134.25, down from ¥905,665,467.53, reflecting a decrease of 26.3%[72]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 40,323,818,887.54, a decrease of 2.05% compared to the end of the previous year[8]. - Total liabilities decreased to ¥32,182,968,711.01 from ¥33,319,372,797.95, a reduction of 3.4%[41]. - Owner's equity increased to ¥8,140,850,176.53 from ¥7,848,910,920.64, a growth of 3.7%[44]. - Cash and cash equivalents decreased to ¥657,025,602.08 from ¥1,099,190,762.52, a decline of 40.2%[45]. - Total liabilities amounted to CNY 33,319,372,797.95, with current liabilities at CNY 31,828,994,088.35[108]. - Non-current liabilities totaled CNY 1,490,378,709.60, contributing to the overall liabilities[108]. - The total equity attributable to shareholders was CNY 6,254,446,734.01, reflecting the company's financial health[108]. - The company has a deferred income of CNY 54,130,049.57, which may impact future earnings[114]. Cash Flow - Cash flow from operating activities for the current period is ¥173,819,313.43, a decrease of 61.49% from ¥451,186,462.12 in the previous period[88]. - Cash inflow from financing activities is ¥20,176,703,830.68, down from ¥33,303,071,038.07 in the previous period, reflecting a decrease of 39.4%[91]. - The net increase in cash and cash equivalents for the current period is ¥239,051,524.32, compared to ¥625,716,157.87 in the previous period, indicating a decrease of 61.83%[91]. - Cash inflow from operating activities totaled 11,351,051,589.76 yuan, down from 13,862,739,190.69 yuan year-on-year[95]. - Cash outflow from operating activities increased to 11,421,850,643.88 yuan compared to 10,866,492,483.18 yuan in the previous period[95]. - Cash inflow from financing activities decreased to 6,165,298,077.33 yuan from 15,449,511,709.40 yuan in the previous period[97]. - Cash outflow from financing activities reduced to 5,964,182,441.56 yuan compared to 18,242,076,807.16 yuan last year[97]. Investments and Expenses - Research and development expenses increased significantly to ¥15,386,379.35 from ¥4,077,042.90, indicating a focus on innovation[53]. - Research and development expenses increased to ¥34,593,150.85 from ¥26,937,499.05, representing a growth of 28.9%[72]. - The total investment income for the current period is reported as -¥28,250,242.41, slightly improved from -¥29,068,979.12[72]. - The company incurred financial expenses of -¥23,404,443.52, a decrease from -¥89,649,132.08 in the previous period, indicating improved financial management[78]. Shareholder Information - The total number of shareholders at the end of the reporting period was 202,207[12]. - The company terminated its non-public stock issuance application from 2019, with the uncertainty of approval for the 2020 non-public stock issuance remaining[19][20].